1 / 12

Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer

Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer. WK Evans, M Wolfson, WM Flanagan, J Oderkirk, J Goffin, J Shin, G Lockwood

min
Download Presentation

Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer WK Evans, M Wolfson, WM Flanagan, J Oderkirk, J Goffin, J Shin, G Lockwood Department of Oncology, McMaster University, Hamilton, Ontario; Statistics Canada, Ottawa, Ontario and the Canadian Partnership Against Cancer, Toronto, Ontario

  2. Canadian Cancer Risk Management Model (CRMM) • A web-based modeling platform that projects the future burden of cancer and its macroeconomic impacts • Simulate current and future cancer control interventions on both the population and the economy • Developed to inform policymakers in government and cancer agencies in Canada about future investments in cancer control

  3. Cancer Risk Conceptual Model

  4. Data Sources

  5. Lung Cancer Management Algorithm Surgery Stage I NSCLC Specialist Diagnostic Workup P Radio Medically inoperable Progression (Relapse) Surveillance post-resection BSC Stage II NSCLC Specialist Diagnostic Workup Surgery Adjuvant Chemo New Lung Primary (re-enter on the left – empty for phase I) Concurrent Adjuvant Chemo &Radio Surveillance P Stage III NSCLC Specialist Diagnostic Workup Family Diagnosis of lung cancer (all cases) Palliative Radio BSC Stage IV NSCLC Specialist Diagnostic Workup 2nd Line Chemo* 3rd Line Chemo* 1st Line Chemo* Best Supportive Care only* BSC BSC PCI Concurrent Adjuvant Chemo & Chest Radio Limited SCLC Specialist Diagnostic Workup Terminal Care 1st Line Chemo** Surveillance P Radio *Palliative Radio given to a % of Stage IV patients after chemotherapy, and a % of patients receiving best supportive care PCI Extensive SCLC Specialist Diagnostic Workup 1st Line Chemo 2nd Line Chemo BSC 5 ** Some may get 2nd line chemo and palliative radio at recurrence Details of costs, transition probabilities, durations and health utilities found in Lung Cancer Management Data 2009-06-30.xls

  6. Impact of Smoking Cessation on Total Direct Healthcare Costs Base case Smoking cessation (10 yrs) Smoking cessation (5 yrs) Smoking cessation (3 yrs) Life-years gained Direct HC costs Cigarette Taxes Base case: Constant smoking rate of 22% savings (reduced revenue) 50% relative reduction reached over 3 years (2010-2012) 646,800 $84 B 50% relative reduction reached over 5 years (2010-2014) 587,000 $656 M $81 B 50% relative reduction reached over 10 years (2010-2019) 469,100 $74 B

  7. Impact of Smoking Reduction 50% reduction achieved over 5 years: Over 20 years, would result in: Decrease in lung cancer cases by 40,200 Decrease in prevalence of lung cancer by 72,400 Reduce deaths from lung cancer by 25,300

  8. Report date: March, 2010 Data source: Cancer Care Ontario, ALR, OCR Notes: 1. Many patients in the "No Treatment" category may not be medically fit for the guideline treatment due to factors we are not currently able to adjust for. Patients may also decline treatment for personal reasons. Others may have been treated outside Ontario. 2. Alternate Treatment: cases receiving a therapy different from that recommended in the guidelines. This may include non-platinum-based chemotherapy or radiation therapy only. 3. Treated Non RCC: patients receiving chemotherapy outside of a cancer centre where the drug regimen is not reported to CCO. 4. Data represents patients diagnosed Between Jan 2007 and Dec 2007, and and resected within 270 days of diagnosis)

  9. Impact of Increasing Adjuvant Chemotherapy Uptake on Health Care Costs and Life Years Gained( Stage II and IIIa, N = 1033) Incremental cost-effectiveness ratio (ICER) = $102 per life year gained Increasing adjuvant chemotherapy uptake rates from 20% to 70% could extend life years by an average of 1.3 years per patient Savings in 2nd-line chemotherapy $1.1M, supportive $394,555 and end of life care $344,434

  10. Lung Cancer Screening Eligibility Criteria Number eligible in Canada in 2011 using NLST eligibility criteria would be 2,184,735

  11. Describes the total annual direct healthcare treatment cost for cases who are initially diagnosed as Stage IV NSCLC between 2011 and 2015 and receive the 1st line chemotherapy (followed by subsequent lines of chemotherapies and/or receive supportive care) Five-year cumulative budgetary impact of introducing TC-beva regimen to the Stage IV 1st line chemotherapy would be $185 million.

  12. Potential Policy Questions that CRMM can Address • Impact of changes in smoking rates by province on the number of lung cancer cases by age, gender, cell type and stage and by province over next 20 years • Impacts (health outcomes and costs) of the introduction of a population-based screening program at the provincial or national level • Likely effect of any new intervention on disease progression, life expectancy, years lived in health, budget impact, cost-effectiveness • Adjuvant therapy for surgically resected lung cancer • New systemic therapy for advanced disease

More Related